2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2970

Incidence and Characteristics of Vasculitis Associated with Monoclonal Antibodies and Peptide Fusion Proteins: A Survey from the French National Pharmacovigilance Database
Abstract Number: 2971

Characteristics and Management of IgA Vasculitis (Henoch-Schönlein purpura) in Adults: Data from the 260 Patients Included in the Igavas Survey
Abstract Number: 2972

Vaccination and Risk of Childhood IgA Vasculitis (Henoch–Schönlein): A Case-Crossover Analysis
Abstract Number: 2973

A Comparison of Caregiving Burden and Impact in Systemic Vasculitis Versus Other Conditions
Abstract Number: 2974

An Outcome Survey of 100 Patients with Cerebral Venous Sinus Thrombosis Due to Behcet’s Syndrome Followed up at a Single, Dedicated Center
Abstract Number: 2975

Increase of Sacroiliitis By Follow-up and Routine CT in Patients with Behcet’s Disease
Abstract Number: 2976

Disease Flares and Persistent Low-Level of Disease: Long-Term Outcome in a Cohort of Patients with BehçEt’s Disease
Abstract Number: 2977

Treatment of Cryoglobulinemic Vasculitis with Sofosbuvir in Four Combination Protocols
Abstract Number: 2978

Psychiatric Involvement and Behcet’S Syndrome: Does Bipolar Disorder Represent a Clinical Feature of the Disease?
Abstract Number: 2979

a Systematic Literature Review on the Treatment of Skin, Mucosa and Joint Involvement of BehçEt’s Syndrome Informing the Eular Recommendations for the Management of BehçEt’s Syndrome
Abstract Number: 2980

Inflammation As an Under-Recognized Cause of Ascending Aortic Aneurysms: A Single-Center Clinical and Pathological Study of 53 Cases over 6 Years
Abstract Number: 2981

Prospective Cohort of Surgically-Diagnosed Aortitis at the Ottawa Hospital
Abstract Number: 2982

Tumor Necrosis Factor Inhibitors and the Risk of Malignancy in the Treatment of Juvenile Idiopathic Arthritis
Abstract Number: 2983

Efficacy and Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, or Adalimumab in Patients with Active Psoriatic Arthritis and an Inadequate Response to Conventional Synthetic Dmards: A Randomized, Placebo‑Controlled, Phase 3 Trial
Abstract Number: 2984

Novel Anti-Malarial Drug Derivative Inhibited Type I Interferon Production and Autoimmune Inflammation through Inhibition of CGAS-Sting Pathway in Trex1-/- Mouse

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].